{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T23:28:48Z","timestamp":1781998128931,"version":"3.54.5"},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The quest for a functional cure for chronic hepatitis B (CHB) remains an elusive objective. Haematopoietic stem cell transplantation (HSCT) may elicit viral clearance by immunological remodelling in recipients with positive HBsAg; however, the factors that determine its effectiveness are yet unknown. The aim of the study is to assess HSCT\u2010induced hepatitis B surface antigen (HBsAg) seroclearance rates and identify immunological mechanisms and combination therapy strategies through meta\u2010analysis and systematic review. In this study, nine trials (308 patients) were subjected to single\u2010arm meta\u2010analysis (R4.4.2 \u2018meta\u2019 package) in accordance with PRISMA\/Cochrane criteria. Heterogeneity was addressed via random\u2010effects models (\n                    <jats:italic>I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200987.1%). Subgroup analysis accounted for donor HBsAb\/recipient HBeAg impacts. The total HBsAg clearance rate was 26% (95% CI: 14%\u201339%), greater than that of standard therapies. Notably, HBsAb\u2010positive donors had significantly enhanced clearance (55% vs. 8%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). HBeAg\u2010negative recipients fared better (29% vs. 2%). In patients who achieved HBsAg loss, HBsAb\u2010positive donors and HBeAg\u2010negative recipients are the most prevalent types (10\/11). Sensitivity analyses confirmed robustness and publication bias was nonsignificant (Egger's\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.271). In conclusion, HSCT demonstrates the potential for functional cure in CHB, providing valuable insights into new immunological therapeutic strategies. More importantly, it serves as a powerful paradigm for identifying the immunological prerequisites for cure, informing the development of safer, targeted immunotherapies.\n                  <\/jats:p>","DOI":"10.1111\/jvh.70114","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:47:16Z","timestamp":1765277236000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single\u2010Arm Meta\u2010Analysis and Systematic Review on Clinical Cure of Chronic Hepatitis B After Haematopoietic Stem Cell Transplantation: Immunoregulatory Mechanisms and Clinical Translational Insights"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5690-6492","authenticated-orcid":false,"given":"He","family":"Ma","sequence":"first","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute Infectious Disease and Hepatology Center of Peking University People's Hospital Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-7488","authenticated-orcid":false,"given":"JiaRui","family":"Zheng","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute Infectious Disease and Hepatology Center of Peking University People's Hospital Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-6148","authenticated-orcid":false,"given":"LinXiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute Infectious Disease and Hepatology Center of Peking University People's Hospital Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZiXuan","family":"Qiu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute Infectious Disease and Hepatology Center of Peking University People's Hospital Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZiLong","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute Infectious Disease and Hepatology Center of Peking University People's Hospital Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanDi","family":"Xie","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute Infectious Disease and Hepatology Center of Peking University People's Hospital Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-6715","authenticated-orcid":false,"given":"Bo","family":"Feng","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute Infectious Disease and Hepatology Center of Peking University People's Hospital Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization \u201cHepatitis B \u201d (2023) accessed February 23 2025 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010b."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.041"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_10_5_1","unstructured":"Asian Pacific Association for the Study of the Liver \u201cAPASL 2025 Beijing Congress \u201d APASL Website (2025) accessed April 1 2025 https:\/\/www.apasl2025beijing.com\/index.html."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010021\u201000549\u20104"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl240023"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010022\u201001880\u20107"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(05)62893\u20100"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010\u2010011\u20100120\u2010x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.1.195.195"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250631"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0168\u20108278(99)80214\u20101"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890\u2010199"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399\u20103046.2002.02037.x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3350\/kjhep.2009.15.2.131"},{"issue":"1","key":"e_1_2_10_17_1","first-page":"S216","article-title":"Clinical Factors Associated With Hepatitis B Virus Seroconversion in HBsAg\u2010Positive Recipients Undergoing Allogeneic Haematopoietic Stem Cell Transplantation With HBsAg\u2010Negative Donors","volume":"46","author":"Luo Y.","year":"2011","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106290"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.452.014k13_452_458"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102005\u201002\u20100698"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/314497"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.132894"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399\u20100012.2003.00070.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.610500"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(19)30119\u20100"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(19)30151\u20107"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2017.00072"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16659"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16782"},{"key":"e_1_2_10_28_1","unstructured":"C.Xie D.Xie Q.Xu et\u00a0al. \u201cThe Everest Project's 5\u2010Year Update: Efficacy of PegIFN\u03b1 Therapy in NA\u2010Suppressed HBeAg\u2010Negative CHB \u201d Presented at: APASL 2024; Abstract O\u20100161."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072\u2010020\u201010"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.01.005"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18448"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.12449\/JCH240525"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901\u2010016\u20100304\u2010z"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.015"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201058870\u20102"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201062445\u20106"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21612"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13709"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010021\u201004730\u20106"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3321\/j.issn:0578\u20101426.2008.04.016"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478\u20103231.2010.02396.x"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13962"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102022\u2010327"},{"issue":"11","key":"e_1_2_10_43_1","first-page":"916","article-title":"Effects of Hepatitis B Virus Surface Antigen on Tim\u20103 Signalling Pathway of Dendritic Cells","volume":"37","author":"Yu Z. J.","year":"2015","journal-title":"Zhejiang Yi Xue"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.11.5707\u20135719.2004"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120228"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/1873\u20103468.14842"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.018"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.06.007"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364\u2010023\u201000534\u20100"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13121100"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.024"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:56:45Z","timestamp":1767013005000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/jvh.70114"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70114","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"2025-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70114"}}